GILDKite, A Gilead CompanyFinished
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
Relapsed/Refractory Mantle Cell Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 95 (final count)
- Started
- Apr 23, 2021
- Main results expected
- Jun 17, 2025
- Fully finished
- Jun 17, 2025
- Results posted
- Aug 18, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants With Objective Response (OR) Per the Lugano Classification According to Independent Radiology Review Committee (IRRC) in Cohort 3
Measured over: Up to 4 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04880434 · record last updated 2026-08-18 · checked 2026-11-09 15:47 UTC